Hugel, a Korean medical aesthetics company, plans to establish a direct sales organization in the United States as it aims to capture a 14 percent share of the U.S. botulinum toxin market by 2030.
Korean aesthetic company Hugel is clear to enter the United States market after a favorable ruling by the country's trade regulator.
Kosdaq-listed Hugel prevailed over Medytox in a preliminary decision by the U.S. International Trade Commission in a dispute over a Botox-related product.
A GS Holdings-Carlyle Group consortium has been selected as the preferred bidder to acquire Medit, a Yeongdeungpo-based company manufacturing 3-D dental scanners.
Hugel's hyaluronic acid filler product won sale approval from health regulators in China, the company said Tuesday.
Botulinum toxin is at the center of another legal battle as Medytox accused Hugel of misappropriation of trade secrets.
The Supreme Court dismissed an appeal filed by the Seoul Regional Office of Food and Drug Safety in an ongoing legal row over the suspension of the sale of Hugel's botulinum toxin products, Hugel said Wednesday.
Hugel's Letybo botulinum toxin product was approved for sale in Britain, the company said Thursday.
Letybo, Hugel’s botulinum toxin product, won marketing approval from health regulators in Austria, the company said Tuesday.
Hugel’s main focus for 2022 is to go global, with the goal of claiming 10 percent of the world market share for botulinum toxin in five years.
Korea JoongAng Daily Sitemap
